FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123546830> ?p ?o ?g. }

• W2123546830 endingPage "2079" @default.
• W2123546830 startingPage "2072" @default.
• W2123546830 abstract "Abstract Hepatocellular carcinoma (HCC) is a major health problem. Most patients with HCC experience a recurrence after resection/ablation or are diagnosed at advanced stages. Sorafenib remains the only approved systemic drug for these patients. Molecular therapies targeting signaling cascades involved in hepatocarcinogenesis have been explored in phase III clinical trials. However, none of the drugs tested have shown positive results in the first-line (brivanib, sunitinib, erlotinib, and linifanib) or second-line (brivanib, everolimus) setting after sorafenib progression. Reasons for failure are heterogeneous and include lack of understanding of critical drivers of tumor progression/dissemination, liver toxicity, flaws in trial design, or marginal antitumoral potency. These trials are also challenging time to progression as a surrogate endpoint of survival. Trials ongoing testing drugs head-to-head versus sorafenib in “all comers” might have difficulties in achieving superior results in the first line. Novel trials are also designed testing drugs in biomarker-based subpopulations of patients with HCC. Most common mutations, however, are undruggable, such as p53 and CTNNB1. Two types of studies are proposed: (i) phase II pivotal proof-of-concept studies testing drugs blocking potential oncogenic addiction loops, such as the one testing MEK inhibitors in RAS+ patients or amplification of FGF19 as a target; and (ii) phase II to III studies using biomarker-based trial enrichment for defining HCC subpopulations, such as the case of enriching for MET-positive tumors. These strategies have been deemed successful in breast, melanoma, and lung cancers, and are expected to change the landscape of trial design of HCC. Clin Cancer Res; 20(8); 2072–9. ©2014 AACR." @default.
• W2123546830 created "2016-06-24" @default.
• W2123546830 creator A5052975894 @default.
• W2123546830 creator A5077891286 @default.
• W2123546830 date "2014-04-15" @default.
• W2123546830 modified "2023-10-17" @default.
• W2123546830 title "Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design" @default.
• W2123546830 cites W1538245709 @default.
• W2123546830 cites W1971837077 @default.
• W2123546830 cites W1974342793 @default.
• W2123546830 cites W1982634085 @default.
• W2123546830 cites W1994193851 @default.
• W2123546830 cites W1997533142 @default.
• W2123546830 cites W2023815439 @default.
• W2123546830 cites W2036922484 @default.
• W2123546830 cites W2042278676 @default.
• W2123546830 cites W2046150599 @default.
• W2123546830 cites W2049937448 @default.
• W2123546830 cites W2051684210 @default.
• W2123546830 cites W2067691895 @default.
• W2123546830 cites W2068127752 @default.
• W2123546830 cites W2077813812 @default.
• W2123546830 cites W2077986225 @default.
• W2123546830 cites W2079586464 @default.
• W2123546830 cites W2088629624 @default.
• W2123546830 cites W2101431311 @default.
• W2123546830 cites W2102942095 @default.
• W2123546830 cites W2104830962 @default.
• W2123546830 cites W2106036268 @default.
• W2123546830 cites W2106787323 @default.
• W2123546830 cites W2106789440 @default.
• W2123546830 cites W2107268345 @default.
• W2123546830 cites W2109746877 @default.
• W2123546830 cites W2115497785 @default.
• W2123546830 cites W2119242310 @default.
• W2123546830 cites W2125065061 @default.
• W2123546830 cites W2128542677 @default.
• W2123546830 cites W2136415416 @default.
• W2123546830 cites W2145803146 @default.
• W2123546830 cites W2147172608 @default.
• W2123546830 cites W2148305615 @default.
• W2123546830 cites W2149908785 @default.
• W2123546830 cites W2153935627 @default.
• W2123546830 cites W2156871508 @default.
• W2123546830 cites W2157535532 @default.
• W2123546830 cites W2163557371 @default.
• W2123546830 cites W2169385554 @default.
• W2123546830 cites W2170845559 @default.
• W2123546830 cites W2532466048 @default.
• W2123546830 cites W2591170673 @default.
• W2123546830 cites W4211105405 @default.
• W2123546830 cites W4242397533 @default.
• W2123546830 cites W4243625103 @default.
• W2123546830 cites W4245784696 @default.
• W2123546830 doi "https://doi.org/10.1158/1078-0432.ccr-13-0547" @default.
• W2123546830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24589894" @default.
• W2123546830 hasPublicationYear "2014" @default.
• W2123546830 type Work @default.
• W2123546830 sameAs 2123546830 @default.
• W2123546830 citedByCount "334" @default.
• W2123546830 countsByYear W21235468302014 @default.
• W2123546830 countsByYear W21235468302015 @default.
• W2123546830 countsByYear W21235468302016 @default.
• W2123546830 countsByYear W21235468302017 @default.
• W2123546830 countsByYear W21235468302018 @default.
• W2123546830 countsByYear W21235468302019 @default.
• W2123546830 countsByYear W21235468302020 @default.
• W2123546830 countsByYear W21235468302021 @default.
• W2123546830 countsByYear W21235468302022 @default.
• W2123546830 countsByYear W21235468302023 @default.
• W2123546830 crossrefType "journal-article" @default.
• W2123546830 hasAuthorship W2123546830A5052975894 @default.
• W2123546830 hasAuthorship W2123546830A5077891286 @default.
• W2123546830 hasBestOaLocation W21235468301 @default.
• W2123546830 hasConcept C121608353 @default.
• W2123546830 hasConcept C126322002 @default.
• W2123546830 hasConcept C141341695 @default.
• W2123546830 hasConcept C143998085 @default.
• W2123546830 hasConcept C203092338 @default.
• W2123546830 hasConcept C2776694085 @default.
• W2123546830 hasConcept C2777802072 @default.
• W2123546830 hasConcept C2778019345 @default.
• W2123546830 hasConcept C2778087573 @default.
• W2123546830 hasConcept C2778695046 @default.
• W2123546830 hasConcept C2779438470 @default.
• W2123546830 hasConcept C2779490328 @default.
• W2123546830 hasConcept C2779699572 @default.
• W2123546830 hasConcept C535046627 @default.
• W2123546830 hasConcept C71924100 @default.
• W2123546830 hasConceptScore W2123546830C121608353 @default.
• W2123546830 hasConceptScore W2123546830C126322002 @default.
• W2123546830 hasConceptScore W2123546830C141341695 @default.
• W2123546830 hasConceptScore W2123546830C143998085 @default.
• W2123546830 hasConceptScore W2123546830C203092338 @default.
• W2123546830 hasConceptScore W2123546830C2776694085 @default.
• W2123546830 hasConceptScore W2123546830C2777802072 @default.
• W2123546830 hasConceptScore W2123546830C2778019345 @default.
• W2123546830 hasConceptScore W2123546830C2778087573 @default.

• next